Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin

By T. Lodise, Jeffrey Graves, A. Evans, E. Graffunder, M. Helmecke, B. Lomaestro, K. Stellrecht. Antimicrobial Agents and Chemotherapy, 2008

607 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Epidemiology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/19d4ff0c7bdc950d9b7193cb096158e704820705

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

1. D. Levine
2. Robert S. Daum
3. S. Cosgrove

In Epidemiology

1. Robert S. Daum

In Infectious Diseases

1. D. Levine
2. Robert S. Daum
3. S. Cosgrove
4. Henry F. Chambers

Citations in the corpus

• Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. (2011, background): “In recent years, several centers have observed an ‘‘MIC creep’’ among MRSA isolates characterized as susceptible by CLSI criteria [331, 332], with the principle concern being the gradual loss of vancomycin activity, because clinical failures appear to be more common among those with MIC values of 2 ”
• Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications (2010, background): “This has been driven partly by studies demonstrating poorer outcomes for vancomycin treatment of MRSA infections with higher vancomycin MICs, even when these MICs are within the susceptible range (112, 184, 298, 332).”